Skip to main content
SpringerLink
Log in

Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 2016; 30: 666–673.

    Article  CAS  Google Scholar 

  2. Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A et al. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort. Leukemia 2016; 30: 1793–1795.

    Article  CAS  Google Scholar 

  3. Nazha A, Narkhede M, Przychodzen B, Zarzour A, Carraway HE, Patel B et al. The impact of different TP53 mutations on outcome in patients with myelodysplastic syndromes (MDS). Clin Lymphoma Myeloma Leuk 2015; 15: S45.

    Article  Google Scholar 

  4. Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD et al. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget 2016; e-pub ahead of print 6 May 2016; doi:10.18632/oncotarget.9200.

  5. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013; 160: 660–672.

    Article  CAS  Google Scholar 

  6. Pellagatti A, Roy S, Genua CD, Burns A, McGraw K, Valletta S et al. Targeted re-sequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia 2016; 30: 247–250.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    D A Sallman, R Komrokji, A List & E Padron

Authors
  1. D A Sallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Komrokji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A List
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Padron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Padron.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sallman, D., Komrokji, R., List, A. et al. Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’. Leukemia 31, 767–768 (2017). https://doi.org/10.1038/leu.2016.257

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.257

  • Springer Nature Limited

Search

Navigation